chartexchange

Bolt Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

GlobeNewswire Inc. | Nov 12, 2026 4:05 PM EST

REDWOOD CITY, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company advancing next-generation, half-life-extended multispecific antibodies, today reported financial results for the third quarter ended September 30, 2026, and provided a business update.

Read original article